Skip to content

CELPHARMA

Active
Public limited companyfounded 2025active for 1 yearLouizalaan 503, 1050 Elsene, Belgium25 active companies are registered at this addressKBO/BCE: BE 1025.475.981
Summary

The computed 12-month bankruptcy probability of CELPHARMA is 1.8% (moderate). The 2025 annual accounts show equity of €1.9m and a net result of €242,673. Its solvency ranks better than 55% of 6,139 sector peers (NACE 46, financial year 2025). The company has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow ReportCompare
CELPHARMAActiveChecked score 56/100
Risk analysis ReportCompare

History

On 14 July 2025, CELPHARMA was incorporated as a public limited company by SBAYE CONSULTING, LEYS IMMO INVEST and 7 natural persons, with a starting capital of €905,909.12 A capital increase in 2025 brought the capital to €1.0m.3 Of the 5 current board members, 5 have served since 2025.2

  1. 1KBO register
  2. 2Belgian Official Gazette, 22-07-2025
  3. 3Belgian Official Gazette, 11-08-2025

Acts, filings and financial milestones

2026
31-08
NBB filing Annual accounts filed
financial year 2025 · full format · 31 days late
2025
11-08
Gazette deed Permanent representative: VAN ACKER Bernard Lucien Jean
Appointment: THINK BVA (présidence conseil d'administration) · Auditor report · Capital contribution30 facts ▸
  • General meeting, 15-07-2025
  • Other provision, “rapport spécial de l’organe d’administration sur augmentation de capital par apport en nature, prix d’émission” (deed in French)
  • Auditor report, “augmentation de capital par apport en nature, 4020 Liège, rue des Vennes 151” (deed in French)
  • Auditor report, “impact direct sur montant de l’actif net, article 7:197 du CSA” (deed in French)
  • Capital contribution (2 times)
  • Share issue, 465732, 480000
  • Share issue, 151319, 155955
  • Share issue, 207683, 214045
  • Share issue, 29108, 30000
  • Share issue, 24257, 25000
  • Share issue, 9703, 10000
  • Share issue, 51394, 52968
  • +18 further facts in this act
22-07
Gazette deed Incorporation
Appointments: THINK BVA, VAN ACKER Thomas Edward Lucien Jean and 3 others · Permanent representative: VAN ACKER Bernard Lucien Jean · Demerger36 facts ▸
  • General meeting, 26-06-2025
  • Demerger, “par constitution d'une nouvelle société, transfert par voie de scission partielle” (deed in French)
  • Other provision, “sur le bureau, documents préalables mis à disposition des actionnaires” (deed in French)
  • Other provision, “dispense de rapports sur projet de scission, actions de la SA CELPHARMA attribuées aux actionnaires de la SA TEONIA proportionnellement” (deed in French)
  • Other provision, “dispense d'actualisation des informations communiquées, article 12:79 dernier alinéa du Code des sociétés et des associations” (deed in French)
  • Other provision, 26-06-2025
  • Auditor report, “4020 Liège, rue des Vennes 151, nomination tardive, impossibilité de se prononcer sur état des stocks” (deed in French) (2 times)
  • Founding capital, €905,908.63
  • Shareholding, 480000, 480000
  • Shareholding, 155955, 155955
  • Shareholding, 214045, 214045
  • Shareholding, 30000, 30000
  • +24 further facts in this act
Gazette deedNBB filing
2 of 2 deeds read

We would like to set cookies. That happens only with your consent. What we measure